Share on LinkedInShare on LinkedIn

ARTICLE · 29 MARCH 2022

Patent Case Summaries | Week Ending March 18, 2022

A weekly summary of the precedential patent-related opinions issued by the Court of Appeals for the Federal Circuit and the opinions designated precedential or informative by the Patent Trial and Appeal Board.

United StatesIntellectual Property

A weekly summary of the precedential patent-related opinions issued by the Court of Appeals for the Federal Circuit and the opinions designated precedential or informative by the Patent Trial and Appeal Board.

Almirall, LLC v. Amneal Pharmaceuticals LLC, et al., No. 2020-2331 (Fed. Cir. (PTAB) Mar. 14, 2022). Opinion by Lourie, joined by Chen and Cunningham.

Amneal petitioned for IPR of a patent owned by Almirall directed to methods of treating dermatological conditions using a topical pharmaceutical composition. The claimed composition requires about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer (A/SA). The claims also recited that the composition "does not comprise adapalene."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from